Tada,

I think my interpretation is correct.  The slide in the kidney presentation is entitled ‘BETonMACE CKD Group – Results’ and provides info on the CKD group versus the remainder (non-CKD) of the study.  Therefore, it indicates that 13% of the non-CKD patients were on SGLT2i and 6% of the CKD patients were on SGLT2i.  6% of 288 CKD patients is 17 or 18 patients.  13% of 2125 non-CKD patients is approx. 280 patients. 

We also know from the post-AHA presentation (slide 35) that in total, 298 BoM patients were on SGLT2i.  Therefore, about 18 CKD patients and 280 non-CKD patients were on SGLT2i. 

Jupe